BioCryst Pharmaceuticals stock gets USD 20.50 target as BioCryst forms board

Published on 10/07/2026 at 06:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 218.25 million, up 45.00 percent year over year. USD 20.50 is the consensus target for BioCryst Pharmaceuticals stock.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals (ISIN US09058V1035) formed a seven-member scientific advisory board on October 5, 2026, while MarketBeat lists a USD 20.50 consensus target for BioCryst Pharmaceuticals stock. The board adds outside scientific expertise as the biotechnology company builds a rare-disease pipeline through external innovation.

Revenue reaches USD 218.25 million

Yahoo Finance reported that total revenue reached USD 218.25 million in the second quarter of 2026, up 45.00 percent year over year on a comparable basis. ORLADEYO revenue rose 10.00 percent to USD 158.20 million, while adjusted operating profit reached USD 113.20 million in the same quarter.

The operating mix matters because the quarter also included USD 55.70 million from the upfront payment in BioCryst's navenibart European license agreement. That payment strengthened the period, while ORLADEYO supplied the recurring commercial base.

Guidance rises to USD 715 million

BioCryst raised its total revenue guidance for fiscal year 2026 to a range of USD 690 million-USD 715 million from USD 635 million-USD 660 million, according to Yahoo Finance. The company maintained ORLADEYO revenue guidance at USD 625 million-USD 645 million and kept adjusted operating-cost guidance at USD 420 million-USD 440 million.

That combination gives investors two different signals: revenue expectations moved higher, but the forecast still depends on ORLADEYO execution and licensing income. Management also said the company generated positive cash flow in the second quarter of 2026 and ended the period with more than USD 350 million in cash and investments.

Competition meets commercial execution

BioCryst's earnings-call transcript said the ORLADEYO paid rate reached 84.00 percent in the second quarter of 2026, compared with 83.00 percent one year earlier. The company also recorded 47 pediatric ORLADEYO prescriptions through July 31, 2026, an early commercial measure that will require further quarters of follow-through.

The same transcript described pressure from newer injectable competitors, although management said overall ORLADEYO retention remained consistent with its market research. The advisory board therefore complements a commercial strategy that must protect the existing product while external research expands the pipeline.

Prior close and valuation

The prior close at Lang & Schwarz was EUR 7.01 on October 5, 2026. BioCryst had a market capitalization of USD 2.0 billion and a 52-week range of USD 6.00 to USD 11.22 as of October 6, 2026.

The further course of trading is shown by the continuously updated real-time quote of BioCryst Pharmaceuticals stock.